ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 32.7 | 27.9 | 34.4 |
| Other income | 0.3 | 0.0 | 0.0 |
| Total income | 33.0 | 27.9 | 34.4 |
| Profit before exceptional items & tax | 4.4 | 5.2 | 6.0 |
| Profit before tax | 4.3 | 5.2 | 6.0 |
| Net profit | 2.7 | 4.2 | 4.0 |
| Operating margin | 13.0% | 18.6% | 17.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -32.50% |
|---|---|
| Net profit, quarter on quarter | -35.70% |
| Revenue, year on year | -4.90% |
NSE results filing, NSE: CURIS. Figures extracted from the filing.
Curis Lifesciences Ltd: key numbers
- Share price
- ₹170.70
- Market cap
- ₹138.0 Cr
- Revenue (annual)
- ₹60.63 Cr
- Net profit (annual)
- ₹6.92 Cr
- P/E (TTM)
- 19.9×Sector 43.8×
- Promoter holding
- 68.03%
- FII holding
- 1.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Curis Lifesciences Ltd
All →Curis Lifesciences Other Announcement
Curis Lifesciences filed its Reg 32 statement of IPO fund utilisation for the half-year to September 30, 2026. The filing reports no deviation or variation, with ₹2,295.11 lakhs utilised against ₹2,752 lakhs proposed.
Curis Lifesciences H1 FY27 Results: Net Profit ₹4.1 Cr, Down 2.4% YoY
Curis Lifesciences Ltd reported revenue from operations of ₹34.1 Cr (+22.2% YoY) and net profit of ₹4.1 Cr (-2.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹4.1 Cr · -2.4% YoY
Curis Lifesciences Other Announcement
Curis Lifesciences Limited informed that it is not required to submit a Corporate Governance Report, as its securities are listed on the SME platform.
Curis Lifesciences Annual General Meeting
Curis Lifesciences Limited conducted its 10th Annual General Meeting on September 29, 2026, to transact various agenda items, including financial statement adoption and director appointments.
Curis Lifesciences Annual General Meeting
Curis Lifesciences filed its 10th AGM notice and FY 2025-26 Annual Report. The meeting is scheduled for September 29, 2026.
Curis Lifesciences Board Meeting Outcome
Curis Lifesciences Limited approved the Director's Report, related party transactions, and scheduled its 10th Annual General Meeting for September 29, 2026. Board outcomes were finalized.